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a  b  s  t  r  a  c  t
Therapeutic  human  immunodeﬁciency  virus  (HIV)  vaccines  aim  to reduce  disease  progression  by induc-
ing  HIV-speciﬁc  T cells.  Vacc-4x  are  peptides  derived  from  conserved  domains  within  HIV-1  p24 Gag.
Previously,  Vacc-4x  induced  T cell responses  in  90%  of  patients  which  were  associated  with  reduced  viral
loads.  Here  we  evaluate  the  effects  of Vacc-4x  boosters  on  T cell  immunity  and  immune  regulation  seven
years  after  primary  immunization.  Twenty-ﬁve  patients  on  effective  antiretroviral  therapy  received  two
Vacc-4x  doses  four  weeks  apart  and were  followed  for 16  weeks.  Vacc-4x  T cell  responses  were mea-
sured  by  proliferation  (CFSE),  INF-,  CD107a,  Granzyme  B, Delayed-Type  Hypersensitivity  test  (DTH)  and
cytokines  and chemokines  (Luminex).  Functional  regulation  of Vacc-4x-speciﬁc  T cell  proliferation  was
estimated  in  vitro  using  anti-IL-10  and  anti-TGF-ß  monoclonal  antibodies.
Vacc-4x-speciﬁc CD8+ T cell  proliferation  increased  in  80%  after  either  the  ﬁrst  (64%)  or  second  (16%)
booster.  Only  40%  remained  responders  after  two boosters  with  permanently  increased  Vacc-4x-speciﬁc
proliferative  responses  (p =  0.005)  and  improved  CD8+ T cell  degranulation,  IFN-  production  and  DTH.  At
baseline,  responders  had  higher  CD8+ T cell  degranulation  (p = 0.05)  and  CD4+ INF-  production  (p  =  0.01),
whereas  non-responders  had  higher  production  of  proinﬂammatory  TNF-,  IL-1  and  IL-1ß  (p  <  0.045)
and  regulatory  IL-10  (p  = 0.07).
Notably,  IL-10  and  TGF-ß  mediated  downregulation  of  Vacc-4x-speciﬁc  CD8+ T  cell  proliferation
increased  only  in  non-responders  (p < 0.001).  Downregulation  during  the  study  correlated  to  higher  PD-1
+expression  on  Vacc-4x-speciﬁc  CD8 T cells  (r = 0.44,  p = 0.037),  but  was  inversely  correlated  to changes
in  Vacc4x-speciﬁc  CD8+ T cell proliferation  (r  = −0.52,  p  =  0.012).
These ﬁndings  show  that  Vacc-4x  boosters  can  improve  T cell  responses  in  selected  patients,  but  also
induce  vaccine-speciﬁc  downregulation  of  T cell  responses  in  others.  Broad  surveillance  of T  cell  functions
during  immunization  may  help  to individualize  boosting,  where  assessment  of vaccine-related  immune
regulation  should  be further  explored  as  a  potential  new  parameter.© 201
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. Introduction
Human immunodeﬁciency virus (HIV) type 1 preferentially tar-
ets and depletes two types of activated CD4+ T cells in primary
nfection; CCR5+CD4+ Th17 mucosal T cells [1] and subsequently
IV-speciﬁc CD4+ T cells. The latter clones are essential in main-
aining effective viral control in collaboration with CD8+ T cells
f the same speciﬁcities [2,3]. In chronic HIV infection there is
n altered balance between immune activation, immune exhaus-
ion and regulation. Recent data suggests that low T regulatory
ell (Treg) responses are associated with viral control in HIV con-
rollers [4] and that protective HIV-speciﬁc CD8+ T cells evade Treg
uppression [5].
Therapeutic  HIV vaccines aim to repair HIV-speciﬁc cellular
mmunity after primary infection by inducing new T cell clones
nd thereby better control viral replication, especially through
olyfunctional HIV-speciﬁc CD8+ T cell responses [6,7]. Thus,
ffective vaccination may  potentially reduce disease progression,
elay initiation of antiretroviral treatment (ART) and help to
ecrease residual viral load levels in already treated patients
8].
Vacc-4x is a therapeutic HIV-1 vaccine candidate derived
rom conserved domains within p24 Gag, designed to stimulate
ellular immune responses [9]. Previously, Vacc-4x stimulated
roliferative T cell responses in 90% of immunized HIV posi-
ive patients [10]. Enhanced T cell responses to Vacc-4x were
ssociated with reduced viral loads during ART interruptions
11,12] and postponed reintroduction of ART [10] without induc-
ng viral immune escape [13]. Furthermore, we have demonstrated
ong-term Vacc-4x-speciﬁc T cell memory in the same cohort
10,14].
The objective of this study was to evaluate how two  booster
mmunizations of Vacc-4x would inﬂuence quantitative and qual-
tative aspects of Vacc-4x-speciﬁc T cell immune responses in
reviously immunized subjects, with the ultimate goal to explore
he potential of developing individualized immunization regi-
en for HIV-infected patients. Although vaccine boosters aim to
trengthen the pool of effector T cells, boosting might theoretically
lso induce or enhance a spectrum of immune regulatory mech-
nisms [15,16]. However, to our knowledge, regulation has not
een assessed during therapeutic HIV vaccine boosters in man. We
ypothesized that responses to two consecutive boosters would be
ifferentiated and that immune regulatory mechanisms might play
 role. We  assessed the regulation of vaccine-speciﬁc T cell prolifer-
tion by the two key inhibitory soluble cytokines IL-10 and TGF-ß
n vitro [16,17]. Instead of characterizing the many possible cellu-
ar sources for these cytokines, we here examined their collective
nﬂuence on T cell effector function in the individual patient. We
ound that changes in this parameter could explain the diversiﬁed
esponses to booster vaccination.
. Materials and methods
.1.  Study participants and study design
Twenty-ﬁve HIV positive patients who had completed the ﬁrst
acc-4x study and who had been on effective ART for at least 6
onths, with viral load <20 copies/ml and with no clinical signs
f immune deﬁciency were included for re-immunization in this
on-randomized single-center, open-label one arm study. Patients
ith previous allergic reactions to Vacc-4x, malignant disease,mmune suppressive therapy, concurrent active infections, as well
s pregnant or breastfeeding women were excluded. Fifteen min-
tes prior to immunizations, low dose GM-CSF (Leukine; Genzyme,
A, USA) was injected intradermally followed by 100 l Vacc-4x(2013) 4611– 4618
(300  g/ml per peptide) intradermally in the same spot at baseline
and after 4 weeks. Clinical examination, general biochemistry and
hematologic analyses, HIV-RNA, CD4 and CD8 cell counts were per-
formed on every visit at study weeks 0, 4 and 16. All blood samples
were collected prior to immunizations.
The study was  approved by the Norwegian Medicine Agency
and the Norwegian South-Eastern Regional Committee for Medical
and Health Research Ethics with written informed consent from all
participants and monitored by Mericon (Skien, Norway).
2.2.  T cell assays
2.2.1.  Proliferation and IL-10 and TGF-  ˇ blocking assays
Peripheral-blood mononuclear cells (PBMC) were labelled with
carboxyﬂuorescein succinimidyl ester (CFSE, Invitrogen Molecu-
lar Probes, OR, USA) as described earlier [9] before stimulation
with Vacc-4x (5 g/ml/peptide) along with unstimulated nega-
tive and positive controls (Staphylococcal enterotoxin B, 0.5 g/ml,
Sigma–Aldrich, MO,  USA). In addition, parallel antigen-stimulated
samples and controls cultures received blocking anti-IL-10 and
anti-TGF-ß monoclonal antibodies (mAbs) at 10 g/ml, according
to the instructions by the manufacturer (R&D Systems Europe,
Abingdon, UK) and described elsewhere [17]. Cells were cultured
in serum-free culture medium (Gibco AIM V, Invitrogen) with
0.5% highly puriﬁed human albumin for 6 days at 37 ◦C and 5%
CO2 before harvesting, staining and preparation for ﬂow cyto-
metric analysis as previously detailed [9]. Cells were stained with
anti-CD3 Paciﬁc Blue, anti-CD8 AmCyan, anti-HLA-DR PE-Cy7 and
7-aminoactinomycin (7-AAD), the latter to exclude nonviable cells
(Becton Dickinson Pharmingen, NJ, USA). Antigen-speciﬁc response
was calculated as difference in percentage of proliferated (CFSEdim),
activated (HLA-DR+) and live (7-AAD−) CD3+ T cell subsets (CD8+ or
CD8− (deﬁned as CD4+), respectively) between antigen-stimulated
and control cultures, as previously detailed [14]. Multiple parallels
were not due to shortage of available cells. IL-10- and TGF--
mediated regulation of proliferation was  estimated by subtracting
antigen-induced proliferation from parallel controls with only IL-
10- and TGF- blocking mAbs (Fig. 1). Flow cytometry data were
obtained with a BD Canto II with BD Diva software v6 and analyzed
in WinList v7 (Verity Software House, ME,  USA).
2.2.2. INF- and CD107a degranulation assays
Freshly isolated PBMC were stimulated with Vacc-4x
(5 g/ml/peptide) at 37 ◦C and 5% CO2 for 6 h followed by
harvesting, staining and preparation for ﬂow cytometric analysis.
Monensin (BD) and FITC-labelled anti-CD107a (eBioscience, CA,
USA) were added prior to stimulation [18]. Two-step surface
staining was performed with biotinylated anti-PD-1 (R&D) and
Streptavidin-APC (Invitrogen), the latter with anti-CD3 and anti-
CD8, followed by permeabilization (PERMII, BD) and intracellular
staining for interferon- (INF-) PE (BD). Cut-off for PD-1 was
determined using the Fluorescence minus one method [19].
2.2.3.  Granzyme B ELISPOT
The  Granzyme B enzyme-linked immunosorbent spot (ELISPOT)
assay was performed according to the instructions by the manu-
facturer (Mabtech, Sweden) with cryopreserved PBMC that were
reconstituted overnight and stimulated in triplicate with Vacc-4x
15-mer overlapping peptides along with positive and negative con-
trols using 200,000 PBMC/well. Spots were counted using an AID
Elispot reader with AID Elispot v5 scanner software (AID GmbH,
Germany) and median values of triplicates were used for analysis.
Spot-forming units (SFU) were adjusted by the number of spots in
negative controls. The proportion of CD8+ T cells in each sample
was enumerated by ﬂow cytometry to calculate SFU per million
CD8+ T cells.
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Fig. 1. (A) Schematic outline of the assay for assessing T cell regulation of vaccine-speciﬁc proliferation. Left panel illustrate that antigen-induced T cell responses, such
as  proliferation, is a net result of proinﬂammatory and regulatory signals. Functional IL-10 and TGF--mediated T cell regulation () is deﬁned here as the difference
in conventional antigen-induced proliferation (left panel) versus antigen-induced proliferation in the presence of anti-IL-10 and anti-TGF-ß monoclonal antibodies (right
panel).  (B) Example of two  study patients with similar conventional proliferative CD8+ T cell responses (CFSEdimHLA-DR+, left panels) to Vacc-4x peptides (0.95% and 0.99%,
respectively) above corresponding unstimulated control. Parallel cultures with additional anti-IL-10 and anti-TGF- (right panels) reveal moderately increased ( = +0.53%,
s er rig
























subject #10, upper right panel) or strongly increased ( = +3.04%, subject #23, low
acc-4x unstimulated control with anti-IL-10 and anti-TGF- only,  being denoted
eptides for subject #23 in the absence (left lower panel) or presence (right lower p
.2.4. Soluble cytokine and chemokine assay
Cytokines and chemokines were measured in supernatants from
ell cultures containing 200,000 PBMC/well from the proliferation
ssay after 24 h stimulation with Vacc-4x. IL-1, IL-8, IL-10, IL-
3, IL-17, IFN--induced protein 10 (IP-10), monocyte chemotactic
rotein-1 (MCP-1), macrophage inﬂammatory protein-1 (MIP-
), RANTES and tumor necrosis factor- (TNF-) were measured
sing the BioPlex XMap technology (TX, USA) with a Luminex IS100
nstrument (BIO-RAD, CA, USA) and Bio-Plex manager Software v6.
he StatLIA software package v3 (Brendan Scientiﬁc Inc., CA, USA)
as used to calculate sample cytokine concentrations.
.2.5. Delayed-type hypersensitivity testing (DTH)
Vacc-4x peptides were injected intradermally without GM-CSF
t study end. The perpendicular diameters of palpable skin inﬁl-
rates were registered after 48 h as previously described [11,20].
.3. Statistics
Responders and non-responders after the ﬁrst (“primary”) or
econd (“overall”) booster were deﬁned by positive or negative dif-
erences relative to baseline in vaccine peptide-speciﬁc CD8+ T cell
esponses, respectively. Mann–Whitney U (MWU), Kruskal–Wallis
est, Spearman Rank, Wilcoxon signed-rank test and Fisher exact
est were used to analyze differences between groups, correlations,
ependent variables and cross-tabulated data, respectively (Statis-
ica v7, StatSoft, OK, USA). Continuous variables are presented as
edian (interquartile ranges, IQR). A p-value ≤0.05 was considered
igniﬁcant.ht middle panel) proliferation above those with Vacc-4x alone after correcting for
wnregulation of CD8+ T cells. The two lower panels shown controls without Vacc-4x
 of anti-IL-10 and anti-TGF- blocking mAbs, respectively.
3.  Results
3.1. Safety and clinical data
Twenty-ﬁve of the 38 patients from the ﬁrst Vacc-4x study
[9] were available and eligible for re-immunization. After primary
immunizations, all continued the 14 weeks per protocol interrup-
tion of ART for 1.8 years (median) and were thereafter treated with
effective ART for 5.4 years (median) before inclusion in the present
study. Clinical data are presented in Table 1.
After two  Vacc-4x booster doses, only mild and transient
discomfort was reported; 15 patients developed moderate local
erythema or swelling at the injection site and ﬁve experienced
additional muscle pain, fever, fatigue and headache after the ﬁrst
booster, whereas 18 patients reported local and three patients
reported systemic symptoms after the second booster. No HIV-
related complications were seen during the study period and
all participants were asymptomatic at study end. Moreover, no
changes were noted for median CD4 cell counts (587 vs. 582
cells/l), CD8 cell counts (1227 vs. 1151 cells/l) or HIV-RNA (<20
copies/ml).
3.2. Various patterns in Vacc-4x induced T cell responses
following booster immunizationsVacc-4x-speciﬁc in vitro responses were measured by T cell pro-
liferation, CD8+ T cell degranulation (CD107a and Granzyme B)
and INF- production with rather large variations (Fig. 2). How-
ever, the data were consistent throughout the study with signiﬁcant
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Table 1
Clinical data at inclusion.
All (n = 25) Overall responders (n = 10) Overall nonresponders (n = 15)
Age (years) 51 (48–56) 52 (49–56) 50 (47–58)
DTH  (mm2)a 79 (39–154) 143b (104–398) 51 (28–133)
Years  since HIV diagnosis 14.7 (13.0–19.4) 15.6 (12.2–20.9) 14.6 (13.6–19.4)
Years  on effective ART 5.4 (3.5–6.1) 5.4 (3.3–6.1) 4.8 (3.8–6.1)
Nadir  CD4 (cells/l) 210 (150–230) 205 (150–230) 210 (150–270)
CD4  count (cells/l) 587 (435–815) 702 (435–873) 566 (423–687)
CD8  count (cells/l) 1227 (956–1571) 1155 (813–1553) 1233 (1026–1780)
HIV  RNA (copies/ml) <20 (<20–<20) <20 (<20–<20) <20 (<20–<20)














Da DTH: delayed-type hypersensitive skin test (induration area) at week 200 of th
b p = 0.056 between overall responders and non-responders (Mann–Whitney U te
orrelations between the CD8+ and CD4+ T cell subsets as well as
or the parameters for degranulation (data not shown).
Robust proliferative CD8+ T cell responses to Gag have con-
istently been related to slow progression of HIV [7,18]. Change
n Vacc-4x proliferative CD8+ T cell responses relative to baseline
as therefore chosen as the primary immunological read-out for
oosting efﬁcacy, in accordance with previous Vacc-4x studies [9].
At baseline, 19 (76%) patients had detectable proliferative CD8+
 cell responses to Vacc-4x (0.90% [0.28–1.32]). Twenty patients
80%) enhanced Vacc-4x CD8+ proliferation at some time point,
ither after the ﬁrst (64%) or the second booster (16%). At the end
f the study, 10 patients (40%) ended up as overall responders with
ig. 2. Vacc-4x-speciﬁc T cell responses at baseline (week 0), after the ﬁrst (week 4) and 
R+-deﬁned proliferation, CD107a, Granzyme B and INF-). Medians and interquartile ral Vacc-4x protocol [10,11].
permanently  improved Vacc-4x CD8+ T cell proliferation relative
to baseline (p = 0.005). The remaining 15 patients (60%) were over-
all non-responders, notably with decreasing Vacc-4x CD8+ T cell
proliferation after two  boosters (p = 0.001), with the same distribu-
tion of randomized Vacc-4x dose arms as overall responders (see
[9]). However, quite different responses after the ﬁrst booster were
observed within each responder group (Fig. 3, right panels): for
example, among overall responding patients, 5 patients achieved
maximal proliferative responses after the ﬁrst booster, but with a
four-fold reduction in proliferation after the second (p = 0.046). In
contrast, the 4 out of the 5 remaining overall responders tended
to reduce responses after the ﬁrst booster. Among the overall
second booster (week 16), measured by four different in vitro assays (CFSEdimHLA-
nge (IQR) indicated for CD8+ () and CD4+ (©) T cells, respectively.
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ppper  left panel) and overall non-responders (−, lower left panel), respectively. Sm
esponse after the ﬁrst booster determined at week 4 (medians, interquartile rang
dashed horizontal lines) are shown (Wilcoxon).
on-responders, 10 patients improved Vacc-4x responses after the
rst booster whereas proliferation decreased in 5 (Fig. 3). Thus,
cross the overall response groups, a subgroup of patients seemed
o proﬁt from the ﬁrst booster only, denoting them as primary
esponders, with the reservation that ﬁrst and second responses
ere evaluated after different period of times relative to boosting.
At  baseline, overall responders had higher frequencies of Vacc-
x-speciﬁc CD8+ T cell CD107a+ degranulation (p = 0.05) and
D4+ T cell INF- production (p = 0.01), whereas some overall
on-responding patients had higher secretion of certain proin-
ammatory cytokines, but also IL-10 (see below). In addition,
rimary responders had higher baseline levels of Vacc-4x-speciﬁcbox-plot panels show these responder groups according to their primary Vacc-4x
d overall range indicated). p-values for groupwise differences relative to baseline
degranulating (CD107a+) CD8+ T cells (p = 0.05, data not shown).
No differences in baseline proliferative response rates (70% and
80%, p = 0.46), clinical parameters, HIV-RNA levels or CD4 cell
counts were seen between overall responders and non-responders
(Table 1).
Additional modalities of Vacc-4x induced CD8+ T cell responses
after two boosters were also assessed and evaluated together.
Nine (90%) overall responders improved at least two  CD8+ T
cell response modalities (mainly degranulation) and 40% of them
even had improvements of more than two, which tended to be
lower for overall non-responders (55% and 7%, respectively; p < 0.07,
Fisher).
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(ig. 4. Supernatant concentrations after stimulation of PBMC with Vacc-4x peptid
IL-1, TNF-, and MIP-1) and inhibitory IL-10 shown for patients with progressiv
he other participants (−, n = 20), p-values indicated. Data are expressed as median
.3. Higher baseline levels of proinﬂammatory soluble factors in
acc-4x overall non-responding patients
Cytokine and chemokine levels were measured in cell culture
upernatants at weeks 0 and 16. At baseline, the overall prolifera-
ive CD8+ T cell response correlated both with Th1 (TNF-; r = 0.55,
 = 0.012) and Th2 cytokines (IL-13; r = 0.51, p = 0.02). Interestingly,
he 5 overall non-responders who lost proliferative responses
lready after the ﬁrst booster, had in fact the highest baseline
evels of the proinﬂammatory factors TNF-, IL-1b, MIP-1b and
ossibly also inhibitory IL-10 in response to in vitro stimulation
ith Vacc-4x peptides (Fig. 4). After two booster immunizations,
verall non-responders increased Vacc-4x induced secretion
f the Th2 cytokine IL-13 (p = 0.003, Wilcoxon) whereas over-
ll responders increased secretion of MCP-1 (p = 0.009). Taken
ogether, at baseline proinﬂammatory mediators, but also IL-10,
ere preferentially produced in those patients who did not proﬁt
n re-immunizations at all, while boosters particularly enhanced
acc-4x-related production of the Th2 cytokine IL-13 in the same
atients.
.4. Delayed type hypersensitivity responses to Vacc-4x in vivo
Multiple  DTHs were given during the initial Vacc-4x protocol [9]
nd in follow up studies. Most patients were anergic before primary
mmunization and developed maximal induration at study week 3
10,11]. The last DTH before reboost was done at study week 200 of
he initial Vacc-4x protocol, approximately three years before the
urrent study. A total of 82% of the reboost patients demonstrated
ositive DTH >10 mm2 at week 200 (79 mm2 [39–154]) with possi-
ly larger DTH in the overall responding reboost patients (Table 1).
In the present study, Vacc-4x DTH was again tested at end of
tudy week 16, twelve weeks after the second booster. Twenty-two
96%) of the 23 patients tested had positive DTH (99 mm2 [64–177]),study baseline, adjusted for levels in control cultures. Proinﬂammatory cytokines
of CD8+ T cell responses after each of the two  booster (+, n = 5) are compared with
and range.
still  with possibly larger indurations in overall responders than
non-responders (p = 0.056). The relevance of this simple in vivo
test was supported by correlations with the last preceding Vacc-4x
DTH (r = 0.57, p = 0.011), current CD8+ T cell proliferation (r = 0.56,
p = 0.006) and increased production of IL-13 (r = 0.63, p = 0.003).
3.5.  Increased IL-10 and TGF-  ˇ mediated downregulation of
Vacc-4x  T cell proliferation in overall non-responding patients
We  next assessed the association between boosting, T cell
proliferation and T cell regulation mediated by the key regulatory
cytokines IL-10 and TGF- as illustrated in Fig. 1. At baseline,
in vitro downregulation of Vacc-4x-speciﬁc proliferation was
similar in magnitude and prevalence between the CD8+ and CD4+
T cell subsets (16 [67%] and 15 [63%]) and between overall respon-
ders and non-responders. Notably, this parameter changed only
in overall non-responders, who downregulated Vacc-4x-speciﬁc
CD8+ T cell proliferation (p < 0.001, Wilcoxon). Consequently,
overall non-responders demonstrated stronger in vitro IL-10 and
TGF-ß mediated downregulation of Vacc-4x-speciﬁc CD8+ T cell
proliferation than overall responders after two  boosters (p = 0.031).
The ﬁnding that two boosters either enhanced proliferation or
induced downregulation of Vacc-4x proliferation was  supported
by an overall negative correlation between these two parame-
ters (Fig. 5). Another inhibitory mechanism of effector T cells is
expression of PD-1 [21,22]. Changes in the downregulation of Vacc-
4x proliferation correlated positively to concurrent changes in
the expression of PD-1 on Vacc-4x-speciﬁc CD8+CD107a+ T cells
(Fig. 5).4.  Discussion
The objective of this study was  to evaluate the effects of
two Vacc-4x boosters on speciﬁc T cell immunity in previously
A. Lind et al. / Vaccine 31 (2013) 4611– 4618 4617













































lorresponding changes (y-axis) in proliferative CD8+ T cell responses (left panel) a
ank correlations and p-values indicated.
mmunized HIV-infected subjects. Based on the substantial diver-
ity in HIV-speciﬁc responses in general [18,23] and the variability
e have seen in Vacc-4x responses [10], we expected differentiated
esponses to boosters and hypothesized a possible link to immune
egulation.
In this cohort, most patients still had detectable Vacc-4x
emory responses more than seven years after the primary immu-
ization. The overall efﬁcacy of two boosters was only 40% in
erms of proliferative CD8+ T cell responses. However, 80% of the
atients were responders at some time point, after either one or two
oosters. Notably, only one patient was identiﬁed who  responded
ositively to the ﬁrst and then again to the second booster, and
0% progressively lost Vacc-4x responsiveness after each booster.
verall responders did not only improve CD8+ proliferation but
lso degranulative capacity, which is an important characteris-
ic of effective cytotoxic effector T cells [24]. Re-immunization
ay  therefore improve several Gag speciﬁc cytotoxic CD8+ T cell
esponse modalities in selected patients. Overall responders also
emonstrated increased Vacc-4x-speciﬁc INF- production and
D107a degranulation, suggesting the induction of polyfunctional
 cells. Another response parameter was DTH which related to clin-
cal outcome after primary Vacc-4x immunizations [10,20]. In this
tudy, DTH marginally improved compared to the last preceding
TH taken three years earlier and also correlated to CD8+ T cell
roliferation.
Nevertheless, most patients (60%) ended up with Vacc-4x-
peciﬁc proliferation below their baseline levels after two  Vacc-4x
oosters. To our knowledge, this is the ﬁrst observation where
nsuccessful boosting of a therapeutic HIV vaccine can be
xplained by increased IL-10 and TGF-ß mediated downregulation
f vaccine-speciﬁc T cell proliferation, in keeping with facilita-
ion of therapeutic vaccination of mice obtained by IL-10 blockade
n vivo [25]. Booster-induced changes in IL-10 and TGF-ß medi-
ted regulation were linked to enhanced expression of inhibitory
D-1 on Vacc-4x-speciﬁc effector cells. Thus, in vitro quantiﬁca-
ion of T cell regulation might be relevant when selecting patients
or vaccine trials as well as for the individualization of booster regi-
ens. For example, our data suggest that some of our current study
atients should not have been boosted at all, and robust prolifera-
ive responses after the ﬁrst booster apparently identiﬁed patients
ho in retrospect should not have been offered a second dose.
owever, further explorative studies should include additional reg-
latory modalities, such as the functional regulation by PD-1 and
TLA-4 [26].
Several aspects of our study and exploratory variable for regu-
ation need to be addressed. For example, use of cut-off thresholdssitively so with PD-1 expression on CD8+CD107a+ T cells (right panel). Spearman
to  deﬁne “positive” or non-acceptance of “negative” antigen-
speciﬁc responses in stimulated samples relative to control might
masque regulation as phenomenon. We  therefore used the raw data
throughout. We  acknowledge that classiﬁcation of responder based
on minute differences in responses relative to baseline in some
patients may  be different by chance and altogether weaken the
statistical analysis, but such cases should be randomly distributed.
Moreover, the limited cohort size calls for conﬁrmatory trials, but
we were not able to recruit all previously vaccinated participants.
In addition, regulation and activation might develop differently
by comparing different peptide booster doses, which was ﬁxed in
this study, or with individualized time intervals between boost-
ers. Since the Th2 cytokine IL-13 increased, it would also have
been interesting to test antibody levels to the Vacc-4x peptides,
which have been negligible in previous studies. It is also possi-
ble that booster-induced T cell regulation may develop differently
with other vaccines or modes of immunization. Ideally, we also
would have wanted some additional data: Firstly, future trials of
therapeutic HIV vaccines with patients on ART should strive for
ultrasensitive HIV RNA. However, this was here hampered mainly
by insufﬁcient plasma volume both from the current trial and
previous follow-up of the cohort as well as lack of facilities in
our region for this test. Secondly, characterization of the cellu-
lar sources of IL-10 and TGF- in each individual patient might
have gained additional relevant information, although the com-
bined actions of regulatory cytokines on T cell effector functions
were in our opinion the most important outcome of this pilot
study.
Conclusively, these ﬁndings show that Vacc-4x boosters vari-
ably improves or dampens T cell responses in different patients
and that boosting should be individualized. Broad surveillance
of T cell functions may  help in this respect and assessment of
vaccine-related immune regulation should be further explored as
a potential new parameter.
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